Stonebridge Capital Advisors LLC Buys 40 Shares of Celgene Corporation (CELG)
Stonebridge Capital Advisors LLC increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.3% during the first quarter, Holdings Channel reports. The firm owned 11,812 shares of the biopharmaceutical company’s stock after buying an additional 40 shares during the period. Stonebridge Capital Advisors LLC’s holdings in Celgene Corporation were worth $1,470,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Motco increased its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter valued at $118,000. Carroll Financial Associates Inc. increased its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the last quarter. Oakworth Capital Inc. increased its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the last quarter. Institutional investors own 78.34% of the company’s stock.
Celgene Corporation (NASDAQ CELG) traded up 0.18% during mid-day trading on Wednesday, reaching $131.60. The company’s stock had a trading volume of 793,940 shares. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The firm’s 50 day moving average price is $134.03 and its 200 day moving average price is $124.75. The stock has a market cap of $102.96 billion, a price-to-earnings ratio of 40.76 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.44 EPS. On average, equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/stonebridge-capital-advisors-llc-buys-40-shares-of-celgene-corporation-celg/1495829.html.
Several research analysts have weighed in on the company. Jefferies Group LLC set a $154.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research note on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price target for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target for the company in a research note on Thursday, August 10th. Robert W. Baird restated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research note on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Celgene Corporation currently has an average rating of “Buy” and a consensus target price of $147.00.
In related news, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 253,761 shares of company stock worth $33,792,445 in the last quarter. Company insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.